Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24(+)CD38(hi) B Cells

Type I interferon is widely used for antiviral therapy, yet has yielded disappointing results toward chronic HBV infection. Here we identify that PEG-IFNα-2b therapy toward persistent infection in humans is a double-edged sword of both immunostimulation and immunomodulation. Our studies of this rand...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Immunol
Auteurs principaux: Fu, Binqing, Wang, Dongyao, Shen, Xiaokun, Guo, Chuang, Liu, Yanyan, Ye, Ying, Sun, Rui, Li, Jiabin, Tian, Zhigang, Wei, Haiming
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7786281/
https://ncbi.nlm.nih.gov/pubmed/33424840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.591269
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires